Scott Clarke, Tizona CEO (Tizona)
Gilead lines up a $1.55B biotech buyout deal as CEO Dan O’Day invests in his latest cancer blockbuster dream
The Gilead BD team has teed up another oncology deal for CEO Dan O’Day.
This time the big biotech is rolling out a $300 million …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
